Osteopontin overexpression in papillary thyroid carcinoma with mineralization by Москаленко, Роман Андрійович et al.
 
 
S74 Virchows Arch (2016) 469 (Suppl 1):S1-S346 
Time only to assess mitotic count and Ki-67 index took 18.0 to 27.3 min. 
From the data of collected 760 colorectal NETs, risk of lymph node 
metastasis in rectal NET was confirmed even in lesions smaller than 10 
mm, and vascular invasion was important predictive factor. Conclusion: 
Our basic data will contribute to establish optimal pathological diagnosis 
and therapeutic system in the future. 
PS-03-015 
Differences in the pathological features of papillary thyroid 
microcarcinomas of <5 mm versus >5 mm: A retrospective analysis  
of 254 cases 
A, Nechifor-Boila*, A. Cota, E. Szasz, C. Carasca, A. Borda  
*UMF Tirgu-Mures, Dept, of Histology, Romania 
 
Objective: The prognostic significance of the tumour size in patients with 
papillary thyroid microcarcinomas (PTMC) remains unclear. The purpose 
of this study was to compare the pathological features of PTMCs of <5 
versus >5 mm in our institution, over a 26 year period. 
Method: We performed a retrospective study on 254 PTMCs (123 cases of 
<5 mm and 131 cases >5 mm) registered in the Department of Pathology, 
Tlrgu-Mure? Emergency County Hospital between 1990 and 2015. 
Pathological data were retrieved from database registers and pathological 
reports. 
Results: The multifocality (p = 0.040), the extrathyroidal extension (p = 
0.0001), the positive resection margin (p = 0.046) and the presence of 
associated thyroiditis (p = 0.002) were all found to be significantly more 
prevalent among PTMCs of >5 mm, compared to PTMCs of <5 mm. Other 
parameters, like tumour histological type or lymph node involvement did 
not differ significantly among the study groups (p = 0.458 and p = 0.949, 
respectively). 
Conclusion: Our study revealed important differences in the pathological 
features of PTMCs of >5 mm, compared to PTMCs of <5 mm. Such results 
might suggest that PTMCs of <5 mm should be managed in a different way 
than other PTMCs. Further studies, on larger number of cases, with long 
follow-up data are however needed to confirm this. 
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Objective: Molecular techniques have recently emerged as a potential 
valuable tool that could improve the diagnostic accuracy of thyroid FNA 
biopsy. The aim of our study was to investigate the feasibility of 
BRAFV600E point mutation detection using archived thyroid FNA smears 
(AT-FNAs). 
Method: Eleven AT-FNAs, corresponding to the Bethesda diagnostic 
categories II (n = 4), III (n = 2), IV (n = 3) and VI (n = 2) were included in 
our study (one smear/case). The DNA extraction protocol was based on a 
precipitation method (MasterPureTM DNA purification kit, Epicentre), 
according to the manufacturer instructions and optimized in our laboratory. 
All cases were subject to RT-PCR amplification and high resolution 
melting analysis for a housekeeping gene (GAPDH) and for BRAF gene, 
respectively. 
Results: We successfully isolated good quantity and purity DNA from all 
our cases (mean concentration 62.47±37.55 ng/p.1; mean purity: 1.47 ± 
0.13). Moreover, the BRAFV600E point mutation could be specifically 
amplified in all these cases (2 positive, 9 negative), whereas the GAPDH 
target was amplifiable in all cases, except for two (DNA concentration 15.3 
and 13 ng/p.1, respectively). 
Conclusion: Detection of BRAFV600E point mutation from AT-FNAs is 
feasible. Our DNA extraction technique offered a good range of DNA 
quality, concentration and purity, allowing reliable applications for further 
molecular analysis. 
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Objective: To establish the relationship between ATRX, HES1, mTOR, 
NOTCH1, PDGFR-|3, VEGFR2 and MGMT expression with predictive 
significance on gastroenteropancreatic neuroendocrine tumours (GEP- 
NETs) and its correlation with microRNA expression (miR-19a, miR- 96, 
miR-145, miR-182, miR-200a). 
Method: A retrospective evaluation of the total samples diagnosed as 
GEP- NETs (period 2003-2016) was conducted, clinical and pathological 
characteristics were evaluated in all cases. Biomarkers expression was 
assessed trough immunohistochemistry using tissue microarrays. 
Simultaneously, microRNAs that were possibly regulating biomarkers 
expression in small intestine and colon were identified applying a 
bioinformatic approach. For the 5 microRNAs identified we measured the 
expression by qRT-PCR.  
Results: 143 cases of GEP-NET average age 55(11-83 years-old). Mainly 
from ileum/jejunum (23,8 %), appendix (19.6 %), colon/cecum/ rectum 
(16,8 %), pancreas (15,4 %) and stomach (14 %) were included. 
Expression was positive in Hesl (95.8 %), Notch 1 (91.6 %), ATRX (89.5 
%), VEGFR2 (74.8 %), PDGFR-(3 (62.9 %), mTOR (39.9 %), and MGMT 
(23.8 %). We also found 4 microRNAs upregulated (miR- 96, miR-145, 
miR-182 and miR-200a) and one downregulated (miR-19a) in tumour 
compare with normal tissue. The high expression of ATRX was correlated 
with the loss of miR-19a expression and the downregulation of MTOR and 
VEGFR2 with the upregulation of miR-96 and miR-200a respectively. 
Conclusion: Our results must conduct to new studies focused on strict 
follow up of specific alternative therapies and biomarkers expression to 
evaluate a possible improve in survival rates of this patients. Finally, 
epigenetic factors such as microRNA expression regulated key cell sig-
naling pathways involve in GEP-NETs. 
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Objective: Pathological mineralization (ectopic calcification) is an often 
finding in papillary thyroid carcinoma (PTC). The concept of pathological 
mineralization in papillary thyroid carcinoma included psammoma’s 
bodies, bone formation, stromal and vascular calcification. Osteopontin 
(OPN) is a glyco-phosphoprotein that is expressed and secreted by 
numerous human cancers. Osteopontin is upregulated at sites of pathologic, 
ectopic calcification—presumably at least in part to inhibit debilitating 
mineralization in these soft tissues. We investigated the expression of OPN 
and her correlation with pathological mineralization in PTC. 
Method: OPN expression was investigated by immunohistochemistry in 
tumours and adjacent thyroid tissue of 11 PTCs with mineralization and 10 
PTCs without pathological mineralization. 
Results: OPN expression was increased in PTC with pathological min-
eralization when compared to those without ectopic calcification (p < 
0.045, Mann-Whitney U test). 
Conclusion: OPN overexpression may be regarded as a protective tissue 
response to the development of ectopic calcification. 
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